Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, December 18, 2014
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Researchers Identify Non-Gluten Proteins as Targets of Immune Response to Wheat in Celiac Disease
The results were reported online in the Journal of Proteome Research.
New Research Unlocks a Mystery of Albinism
A team led by Brown University biologists has discovered the way in which a specific genetic mutation appears to lead to the lack of melanin production underlying a form of albinism.
Predicting Sepsis
Altered white-blood-cell motion in burn patients may warn of infection.
Study Finds Genetic Clue To Menopause-Like Condition In Young Women
NIH-funded research may also contribute to understanding normal menopause.
Cutting Out the Cellular Middleman
New technology directly reprograms skin fibroblasts for a new role.
Therapeutic Strategy May Treat a Childhood Neurological Disorder
Researchers have identified a possible therapy to treat neurofibromatosis type 1 or NF1.
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Anti-Diabetic Drug Springs New Hope for Tuberculosis Patients
Drug for treating diabetes can double up as adjunct treatment for tuberculosis.
People May Inherit ‘Gut’ Bacteria That Cause Crohn’s Disease And Ulcerative Colitis
Discovery is another step toward prevention and treatment of 1.6 million Americans with inflammatory bowel disease.
Long Noncoding RNAs: A Novel Prognostic Marker in Older Patients with Acute Leukemia
This study describes a new marker that might help doctors choose the least toxic, most effective treatment for older patients with acute myeloid leukemia.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn